NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000014272

Registered date:16/06/2014

Evaluation of anti-IgE antibody therapy in the patients with wheat allergy

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedWheat allergy
Date of first enrollment2014/06/02
Target sample size20
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Subcutaneous injection of 150 mg of Omalizumab (Novartis Pharma, Japan) once every four weeks, 3 times in all.

Outcome(s)

Primary OutcomeTo evaluate the sensitization status before and after the therapy using basophil activation test, specific IgE test, and enzyme-linked immunosorbent assay.
Secondary OutcomeFood challenge test before and after the treatment if available.

Key inclusion & exclusion criteria

Age minimumNot applicable
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteriaPatients who had been administrated of Omalizumab in history, and patients who receive immunosuppressive drugs.

Related Information

Contact

public contact
Name Yuko Chinuki
Address Enya 89-1, Izumo, Shimane 693-8501, Japan Japan
Telephone 0853-20-2210
E-mail ychinuki@med.shimane-u.ac.jp
Affiliation Shimane University Hospital Dermatology
scientific contact
Name Yuko Chinuki
Address Enya 89-1, Izumo, Shimane 693-8501, Japan Japan
Telephone 0853-20-2210
E-mail ychinuki@med.shimane-u.ac.jp
Affiliation Shimane University Hospital Dermatology